Suchergebnisse - "Lebwohl, Mark"

PubPharm (1.015)

1

Deucravacitinib in plaque psoriasis : 2-year safety and efficacy results from the phase III POETYK trials

enthalten in: The British journal of dermatology | 2024

von Lebwohl, M. | Warren, R. | Sofen, H. | +12

CommentIn: Br J Dermatol. 2024 Feb 26;:. - PMID 38407434

2

Narrowband UVB phototherapy : a consensus on standards of care

enthalten in: Journal of the American Academy of Dermatology | 2024

von Richard, E. | Buzney, E. | Lebwohl, M. | +2

3

Bimekizumab safety in moderate to severe plaque psoriasis : Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

enthalten in: Journal of the American Academy of Dermatology | 2024

von Lebwohl, M. | Merola, J. | Strober, B. | +9

4

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis : a 52-week, phase 2, open-label trial

enthalten in: Journal of the American Academy of Dermatology | 2024

von Stein Gold, L. | Adam, D. | Albrecht, L. | +18

5

Generalized pustular psoriasis : A consensus statement from the National Psoriasis Foundation

enthalten in: Journal of the American Academy of Dermatology | 2024

von Armstrong, A. | Elston, C. | Elewski, B. | +32

6

Executive Summary : From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis

enthalten in: Journal of the American Academy of Dermatology | 2024

von James, W. | Rosenberg, A. | Wu, J. | +22

7

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis : pooled data from up to 3 years of treatment in randomized phase III trials

enthalten in: The British journal of dermatology | 2024

von Gordon, K. | Langley, R. | Warren, R. | +8

CommentIn: Br J Dermatol. 2023 Nov 18;:. - PMID 37979159

8

Deucravacitinib in moderate-to-severe plaque psoriasis : Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Strober, B. | Blauvelt, A. | Warren, R. | +12

9

Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab : Analysis of phase 2/3 randomized trials

enthalten in: Journal of the American Academy of Dermatology | 2024

von Blauvelt, A. | Armstrong, A. | Merola, J. | +6

10

Safety of Secukinumab from 1 Million Patient-Years of Exposure : Experience from Post-Marketing Setting and Clinical Trials

enthalten in: Dermatology and therapy | 2024

von Sun, R. | Bustamante, M. | Gurusamy, V. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[102]